LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Proteinuria After Acute Kidney Injury Predicts Development of Progressive Disease

By LabMedica International staff writers
Posted on 03 Feb 2020
Image: Kidney specimen from patient who died with acute kidney injury. Image shows marked pallor of the cortex, contrasting to the darker areas of surviving medullary tissue (Photo courtesy of Wikimedia Commons)
Image: Kidney specimen from patient who died with acute kidney injury. Image shows marked pallor of the cortex, contrasting to the darker areas of surviving medullary tissue (Photo courtesy of Wikimedia Commons)
A report has suggested that testing recently hospitalized kidney patients for proteinuria could be a way to identify those at higher risk for developing progressive kidney disease, which could require dialysis or surgery.

Clinicians agree that among patients who had acute kidney injury (AKI) during hospitalization, there is a need to improve risk prediction so that those at highest risk for subsequent loss of kidney function are identified for appropriate follow-up.

To this end, investigators at the University of California, San Francisco (USA) and colleagues at several other institutions worked with participants in The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study. This was a multicenter prospective cohort study including four clinical centers in North America that included 1538 patients enrolled three months after hospital discharge between December 2009 and February 2015. Of the 1538 participants, 769 (50%) had AKI during hospitalization.

To detect proteinuria, the investigators measured urine albumin-to-creatinine ratio (ACR) three months after hospital discharge. The mean age of the patients was 65 years, and the median urine ACR was 15 milligrams per gram. Overall, 547 (37%) of the participants were women and 195 (13%) were black.

Results revealed that after a median follow-up of 4.7 years, 138 (9%) participants had kidney disease progression. Higher post-AKI urine ACR level was associated with increased risk of kidney disease progression, and urine ACR measurement was a strong discriminator for future kidney disease progression. The performance of urine ACR was stronger in patients who had had AKI than in those who had not.

"There should be much more emphasis on the testing of proteinuria after AKI to identify high-risk patients," said first author Dr. Chi-yuan Hsu, professor of nephrology at the University of California, San Francisco. "This simple test carries important prognostic information not conveyed by serum creatinine. Too many providers rely on serum creatinine alone to assess the health of the kidneys, but they should not be falsely assured by the latter. Having a more complete picture of kidney health is necessary for proper clinical decision-making."

"Most patients with acute kidney injury are unaware of their condition, lack understanding of its natural history or predisposing factors, and desire more information," said Dr. Hsu. "However, few discharge communications currently provided to these patients explain the condition or provide recommendations for care, which is needed throughout the care continuum."

The AKI study was published in the January 27, 2020, online edition of the journal JAMA Internal Medicine.

Related Links:
University of California, San Francisco

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more